Ad-apoptin is a recombinant oncolytic adenovirus constructed by our laboratory that can express apoptin. It can selectively kill
tumor cells without damaging normal cells. This study investigated the effects of Ad-apoptin on glycolysis, migration and invasion of
non-small cell lung cancer. Cell viability and apoptosis were detected by
CCK-8 and flow cytometry, respectively. Glycolysis was investigated by
glucose consumption,
lactic acid production and glycolytic key
enzyme protein levels. Migration and invasion were evaluated via wound healing, transwell assays and epithelial-mesenchymal transition (EMT)
protein levels. The interaction between apoptin and AMPK was detected by Co-IP. A nude mice
tumor model was established to investigate the anti-
cancer role of Ad-apoptin in vivo. The results showed that Ad-apoptin inhibits cell viability and induces apoptosis of A549 and NCI-H23 cells. Ad-apoptin can reduce the
glucose uptake and lactic production in
lung cancer cells, and reduce the expression of related glycolysis-limiting
enzymes. At the same time, Ad-apoptin inhibited the migration and invasion of
lung cancer. Immunoprecipitation showed that apoptin and AMPK could interact directly. Moreover, knockdown of AMPK significantly attenuated the inhibitory effect of Ad-apoptin on glycolysis, migration and invasion of A549 and NCI-H23 cells. Ad-apoptin can inhibit the growth of
tumors in nude mice. Compared with the control group, Ad-apoptin had a significant inhibitory effect on AMPK knockdown
tumors. The immunohistochemical results of
tumor tissues were consistent with those in vitro. Collectively, Ad-apoptin targets AMPK and inhibits glycolysis, migration and invasion of
lung cancer cells through the AMPK/mTOR signaling pathway. This suggests that Ad-apoptin may have therapeutic potential for
lung cancer by targeting AMPK activation.